{"id":71392,"date":"2026-05-20T08:54:38","date_gmt":"2026-05-20T08:54:38","guid":{"rendered":"https:\/\/medsbase.com\/ll-37\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ll-37","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/ll-37\/","title":{"rendered":"LL-37\uff08\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\u6297\u83cc\u30da\u30d7\u30c1\u30c9\uff09"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 LL-37\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>LL-37<\/strong> (also called Cathelicidin Antimicrobial Peptide, CAP-18, or FALL-39) is a 37-amino-acid amphipathic \u03b1-helical host-defense peptide \u2014 the only human cathelicidin. It is released by proteinase-3 cleavage from the inactive proform (hCAP-18) and combines direct broad-spectrum antimicrobial activity (against bacteria, fungi, enveloped viruses, and biofilms) with potent immunomodulatory effects: LPS neutralisation, chemotaxis of neutrophils\/monocytes\/T-cells, anti-biofilm action, and pro-angiogenic wound-healing signalling. LL-37 is studied across antimicrobial-resistance studies, wound-healing, atherosclerosis, psoriasis pathogenesis, and oncology. Supplied in 5 mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">154947-66-7 (LL-37 \u30d5\u30ea\u30fc\u30d9\u30fc\u30b9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u30bf\u30a4\u30d7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">37\u30a2\u30df\u30ce\u9178\u304b\u3089\u306a\u308b\u4e21\u89aa\u5a92\u6027\u03b1\u30d8\u30ea\u30c3\u30af\u30b9\u30ab\u30c1\u30aa\u30f3\u6027\u6297\u83cc\u5bbf\u4e3b\u9632\u5fa1\u30da\u30d7\u30c1\u30c9\uff1b\u552f\u4e00\u306e\u30d2\u30c8\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\uff08CAMP\u907a\u4f1d\u5b50\u7523\u7269\uff09\uff1b\u4e0d\u6d3b\u6027\u524d\u99c6\u4f53hCAP-18\u306e\u30d7\u30ed\u30c6\u30a4\u30ca\u30fc\u30bc3\u5207\u65ad\u306b\u3088\u308a\u653e\u51fa\u3055\u308c\u308b\u6d3b\u6027C\u672b\u7aef\u30da\u30d7\u30c1\u30c9\uff1b\u307e\u305f\u3001CAP-18\uff0818 kDa\u524d\u99c6\u4f53\u306eC\u672b\u7aef\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\u6297\u83cc\u30da\u30d7\u30c1\u30c9\uff09\u304a\u3088\u3073FALL-39\uff08\u4ee5\u524d\u306e\u914d\u5217\u6c7a\u5b9a\u3067N\u672b\u7aef\u306eF\u6b8b\u57fa\u3092\u542b\u3080\u5834\u5408\uff09\u3068\u3082\u547c\u3070\u308c\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u5f0f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>205<\/sub>H<sub>340<\/sub>N<sub>60<\/sub>O<sub>53<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4,493.3 Da<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u914d\u5217<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) \u2014 \u76f4\u9396\u72b637\u6b8b\u57fa\u30ab\u30c1\u30aa\u30f3\u6027\u30da\u30d7\u30c1\u30c9\uff1b\u4e2d\u6027pH\u3067\u6b63\u5473+6\u306e\u96fb\u8377\uff1b\u8102\u8cea\/\u819c\u74b0\u5883\u3067\u4e21\u89aa\u5a92\u6027\u03b1\u30d8\u30ea\u30c3\u30af\u30b9\u306b\u6298\u308a\u305f\u305f\u307e\u308c\u307e\u3059\u3002\u904a\u96e2N\u672b\u7aef\u304a\u3088\u3073C\u672b\u7aef\uff1b\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u306a\u3057\u3001\u30a2\u30b7\u30eb\u5316\u306a\u3057\u3001PEG\u5316\u306a\u3057\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\uff08\u767d\u8272\u301c\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8 \u00b0C\uff08\u51b7\u8535\u5eab\uff09\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f\u221220 \u00b0C\u3067\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8 \u00b0C\u3001\u7d0414\uff5e28\u65e5\u4ee5\u5185\u306b\u3054\u4f7f\u7528\u304f\u3060\u3055\u3044\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u878d\u89e3\u306e\u7e70\u308a\u8fd4\u3057\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002\u30ab\u30c1\u30aa\u30f3\u6027\u6297\u83cc\u30da\u30d7\u30c1\u30c9\u306f\u30d7\u30e9\u30b9\u30c1\u30c3\u30af\u8868\u9762\u306b\u5438\u7740\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u30b9\u30c8\u30c3\u30af\u306e\u4fdd\u5b58\u3084\u5e0c\u91c8\u306b\u306f\u4f4e\u5438\u7740\u30c1\u30e5\u30fc\u30d6\uff08\u30b7\u30ea\u30b3\u30f3\u30b3\u30fc\u30c6\u30a3\u30f3\u30b0\u307e\u305f\u306fProtein LoBind\uff09\u306e\u4f7f\u7528\u3092\u304a\u3059\u3059\u3081\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\u3001\u6ec5\u83cc\u6c34\u3001\u307e\u305f\u306f\u5e0c\u9162\u9178\uff080.01\uff5e0.1%\uff09\u306b\u9ad8\u3044\u6eb6\u89e3\u6027\u3092\u793a\u3057\u307e\u3059\u3002\u9178\u6027\u304b\u3089\u4e2d\u6027\u306epH\u3067\u518d\u6eb6\u89e3\u3057\u3001\u30b9\u30c8\u30c3\u30af\u6eb6\u6db2\u306b\u306f\u9ad8\u5869\u6fc3\u5ea6\u3084\u5f37\u5869\u57fa\u6027\u306e\u7de9\u885d\u6db2\u3092\u4f7f\u7528\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u4e21\u89aa\u5a92\u6027\u03b1\u30d8\u30ea\u30c3\u30af\u30b9\u306f\u9ad8\u6fc3\u5ea6\u3067\u51dd\u96c6\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u305f\u3081\u3001\u4f7f\u7528\u76f4\u524d\u306b\u4f7f\u7528\u6fc3\u5ea6\u306b\u5e0c\u91c8\u3057\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>LL-37\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>LL-37<\/strong> \u306f\u3001\u30d2\u30c8\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\u6297\u83cc\u30da\u30d7\u30c1\u30c9hCAP-18\u306e\u30bf\u30f3\u30d1\u30af\u8cea\u5206\u89e3\u5207\u65ad\u306b\u3088\u308a\u653e\u51fa\u3055\u308c\u308b\u6d3b\u6027\u578bC\u672b\u7aef37\u30a2\u30df\u30ce\u9178\u30da\u30d7\u30c1\u30c9\u3067\u3042\u308a\u3001\u30d2\u30c8\u306b\u304a\u3051\u308b\u552f\u4e00\u306e\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\u907a\u4f1d\u5b50\u7523\u7269\u3067\u3001\u30b3\u30fc\u30c9\u3055\u308c\u3066\u3044\u308b\u306e\u306f <em>CAMP<\/em> gene on chromosome 3. The peptide takes its name from its first two residues (Leu-Leu) and its length (37 residues). It belongs to the cathelicidin family of innate-immunity host-defense peptides found across most vertebrate lineages and represents the central effector molecule in the human cathelicidin arm of innate immunity, alongside the defensin family. Inactive hCAP-18 proform is produced in neutrophil granules, in epithelial surfaces (skin keratinocytes, respiratory and gut epithelium), and in lower amounts by macrophages, NK cells, mast cells, B-cells, and \u03b3\u03b4 T-cells. Activation occurs by proteinase-3 cleavage (in neutrophils) or by kallikrein-5\/kallikrein-7 (in skin), liberating the bioactive 37-mer that adopts a strongly amphipathic \u03b1-helical conformation in membrane-mimetic environments. The peptide carries a +6 net positive charge at neutral pH, with cationic lysine and arginine residues concentrated on one face of the helix and hydrophobic leucine, phenylalanine, isoleucine, and valine residues on the opposing face \u2014 the canonical &#8220;amphipathic \u03b1-helix&#8221; architecture that enables selective interaction with negatively-charged microbial membranes. LL-37 combines two distinct host-defense modalities in a single peptide. Its <strong>\u76f4\u63a5\u7684\u306a\u6297\u83cc\u6d3b\u6027<\/strong> \u306f\u3001\u30b0\u30e9\u30e0\u967d\u6027\u83cc\uff08\u30e1\u30c1\u30b7\u30ea\u30f3\u8010\u6027 <em>S. aureus<\/em>, \u3001MRSA\uff09\u3001\u30b0\u30e9\u30e0\u9670\u6027\u83cc\uff08 <em>E. coli<\/em>, <em>K. pneumoniae<\/em>, <em>P. aeruginosa<\/em>\uff09\u3001\u30a8\u30f3\u30d9\u30ed\u30fc\u30d7\u30a6\u30a4\u30eb\u30b9\uff08HSV-1\u3001\u30a4\u30f3\u30d5\u30eb\u30a8\u30f3\u30b6\u3001RSV\uff09\u3001\u771f\u83cc\uff08<em>\u30ab\u30f3\u30b8\u30c0<\/em>\uff09\u3001\u5fae\u751f\u7269\u30d0\u30a4\u30aa\u30d5\u30a3\u30eb\u30e0\u3002 <strong>\u514d\u75ab\u8abf\u7bc0\u6d3b\u6027<\/strong> \u7d30\u83cc\u6027\u30ea\u30dd\u591a\u7cd6\uff08LPS\uff09\u304a\u3088\u3073\u30ea\u30dd\u30c6\u30a4\u30b3\u9178\u306e\u7d50\u5408\u3068\u4e2d\u548c\u3001\u30db\u30eb\u30df\u30eb\u30da\u30d7\u30c1\u30c9\u53d7\u5bb9\u4f53\u69d81\uff08FPRL1\/FPR2\uff09\u3092\u4ecb\u3057\u305f\u597d\u4e2d\u7403\uff0f\u5358\u7403\uff0fT\u7d30\u80de\uff0f\u80a5\u6e80\u7d30\u80de\u306e\u8d70\u5316\u6027\u3001TLR\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u306e\u8abf\u7bc0\u3001LPS\u8a98\u767a\u6027\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u30b9\u30c8\u30fc\u30e0\u306e\u6291\u5236\u3001\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bFPRL1\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3092\u4ecb\u3057\u305f\u8840\u7ba1\u65b0\u751f\u306e\u8a98\u5c0e\u3001\u304a\u3088\u3073\u5275\u50b7\u6cbb\u7652\u306b\u304a\u3051\u308b\u30b1\u30e9\u30c1\u30ce\u30b5\u30a4\u30c8\u904a\u8d70\u306e\u523a\u6fc0\u304c\u542b\u307e\u308c\u307e\u3059\u3002LL-37\u306e\u8abf\u7bc0\u7570\u5e38\u306f\u3001\u4e7e\u766c\uff08\u904e\u5270\u306aLL-37\u304c\u81ea\u5df1DNA\u3068\u8907\u5408\u4f53\u3092\u5f62\u6210\u3057\u3066\u5f62\u8cea\u7d30\u80de\u69d8\u6a39\u72b6\u7d30\u80de\u3092\u6d3b\u6027\u5316\u3059\u308b\uff09\u3001\u30a2\u30c6\u30ed\u30fc\u30e0\u6027\u52d5\u8108\u786c\u5316\u75c7\u3001\u7279\u5b9a\u306e\u304c\u3093\u306e\u75c5\u56e0\u306b\u95a2\u4e0e\u3057\u3066\u3044\u307e\u3059\u3002LL-37\u306f <strong>\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 \u819c\u7834\u58ca\uff0b\u514d\u75ab\u8abf\u7bc0<\/h2>\n<p>LL-37 acts through three principal mechanisms documented in published studies:<\/p>\n<ul>\n<li><strong>\u4e21\u89aa\u5a92\u6027\u03b1\u30d8\u30ea\u30c3\u30af\u30b9\u633f\u5165\u306b\u3088\u308b\u9078\u629e\u7684\u5fae\u751f\u7269\u819c\u7834\u58ca<\/strong> \u2014 \u30d0\u30eb\u30af\u6c34\u6eb6\u6db2\u4e2d\u3067\u306f\u3001LL-37\u306f\u5927\u90e8\u5206\u304c\u69cb\u9020\u3092\u6301\u305f\u306a\u3044\u72b6\u614b\u3067\u3059\u304c\u3001\u9670\u6027\u306b\u8377\u96fb\u3057\u305f\u5fae\u751f\u7269\u819c\uff08\u30db\u30b9\u30d5\u30a1\u30c1\u30b8\u30eb\u30b0\u30ea\u30bb\u30ed\u30fc\u30eb\u3001\u30ab\u30eb\u30b8\u30aa\u30ea\u30d4\u30f3\u3001\u30ea\u30dd\u30c6\u30a4\u30b3\u9178\u3001\u307e\u305f\u306fLPS\u306b\u5bcc\u3080\uff09\u3068\u63a5\u89e6\u3059\u308b\u3068\u3001\u8fc5\u901f\u306b\u4e21\u89aa\u5a92\u6027\u03b1\u30d8\u30ea\u30c3\u30af\u30b9\u306b\u6298\u308a\u7573\u307e\u308c\u307e\u3059\u3002\u967d\u30a4\u30aa\u30f3\u9762\u304c\u9670\u30a4\u30aa\u30f3\u6027\u306e\u819c\u8868\u9762\u3068\u76f8\u4e92\u4f5c\u7528\u3057\u3001\u758e\u6c34\u9762\u304c\u8102\u8cea\u4e8c\u91cd\u5c64\u306b\u633f\u5165\u3055\u308c\u307e\u3059\u3002\u30da\u30d7\u30c1\u30c9\u5bfe\u8102\u8cea\u6bd4\u304c\u95be\u5024\u306b\u9054\u3059\u308b\u3068\u3001\u3053\u308c\u306b\u3088\u308a\u30c8\u30ed\u30a4\u30c0\u30eb\u578b\u30dd\u30a2\u307e\u305f\u306f\u300c\u30ab\u30fc\u30da\u30c3\u30c8\u300d\u69d8\u306e\u819c\u5d29\u58ca\u304c\u5f15\u304d\u8d77\u3053\u3055\u308c\u3001\u5fae\u751f\u7269\u7d30\u80de\u304c\u8131\u5206\u6975\u3057\u3001\u5fc5\u9808\u306e\u819c\u9593\u52fe\u914d\u304c\u7834\u58ca\u3055\u308c\u307e\u3059\u3002\u54fa\u4e73\u985e\u306e\u7d30\u80de\u819c\u306f\u3001\u5916\u5074\u30ea\u30fc\u30d5\u30ec\u30c3\u30c8\u304c\u53cc\u6027\u30a4\u30aa\u30f3\u6027\uff08\u30db\u30b9\u30d5\u30a1\u30c1\u30b8\u30eb\u30b3\u30ea\u30f3\u3001\u30b9\u30d5\u30a3\u30f3\u30b4\u30df\u30a8\u30ea\u30f3\uff09\u3067\u3042\u308a\u3001\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u304c\u5b58\u5728\u3059\u308b\u3053\u3068\u3067\u4fdd\u8b77\u3055\u308c\u3066\u304a\u308a\u3001\u3053\u308c\u306b\u3088\u308a\u5e83\u7bc4\u306b\u7d30\u80de\u6bd2\u6027\u3092\u6301\u3064\u754c\u9762\u6d3b\u6027\u5264\u3068\u533a\u5225\u3055\u308c\u308b\u3042\u308b\u7a0b\u5ea6\u306e\u5fae\u751f\u7269\u9078\u629e\u6027\u304c\u3082\u305f\u3089\u3055\u308c\u307e\u3059\u3002<\/li>\n<li><strong>LPS\u4e2d\u548c\u304a\u3088\u3073TLR4\u7d4c\u8def\u8abf\u7bc0<\/strong> \u2014 LL-37 binds directly to bacterial lipopolysaccharide (LPS) with high affinity, sequestering it from the TLR4 \/ MD-2 \/ CD14 receptor complex. This blocks LPS-driven NF-\u03baB activation, reduces downstream TNF-\u03b1 \/ IL-6 \/ IL-1\u03b2 release, and protects host tissue from sepsis-like cytokine storms during severe Gram-negative infections. The same property makes LL-37 a tool for dissecting LPS-driven signalling.<\/li>\n<li><strong>FPRL1\uff08\u30db\u30eb\u30df\u30eb\u30da\u30d7\u30c1\u30c9\u53d7\u5bb9\u4f53\u69d81\uff09\u3092\u4ecb\u3057\u305f\u514d\u75ab\u8abf\u7bc0\u3068\u4e0b\u6d41\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054<\/strong> \u2014 LL-37\u306f\u3001\u81ea\u7136\u514d\u75ab\u30a8\u30d5\u30a7\u30af\u30bf\u30fc\u7d30\u80de\u306b\u5e83\u304f\u767a\u73fe\u3059\u308bG\u30bf\u30f3\u30d1\u30af\u8cea\u5171\u5f79\u53d7\u5bb9\u4f53\u3067\u3042\u308bFPRL1\uff08FPR2\uff09\u306b\u7d50\u5408\u3059\u308b\u3053\u3068\u3067\u3001\u597d\u4e2d\u7403\u3001\u5358\u7403\u3001T\u7d30\u80de\u306b\u5bfe\u3059\u308b\u5316\u5b66\u8a98\u5f15\u7269\u8cea\u3068\u3057\u3066\u4f5c\u7528\u3057\u307e\u3059\u3002\u540c\u3058\u53d7\u5bb9\u4f53\u304c\u5185\u76ae\u7d30\u80de\u4e0a\u3067LL-37\u306e\u8840\u7ba1\u65b0\u751f\u4fc3\u9032\u4f5c\u7528\u3092\u5a92\u4ecb\u3057\u3001\u5185\u76ae\u7d30\u80de\u306e\u5897\u6b96\u3001\u904a\u8d70\u3001\u7ba1\u5f62\u6210\u3092\u523a\u6fc0\u3057\u307e\u3059\u3002\u5275\u50b7\u518d\u4e0a\u76ae\u5316\u6642\u306e\u30b1\u30e9\u30c1\u30ce\u30b5\u30a4\u30c8\u904a\u8d70\u3082FPRL1\u4f9d\u5b58\u6027\u3067\u3059\u3002\u3055\u3089\u306b\u3001\u3053\u306e\u30da\u30d7\u30c1\u30c9\u306f\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u4e0a\u306e\u30d7\u30ea\u30f3\u53d7\u5bb9\u4f53P2X7\u306b\u3082\u4f5c\u7528\u3057\u3001\u30a4\u30f3\u30d5\u30e9\u30de\u30bd\u30fc\u30e0\u8abf\u7bc0\u306b\u5bc4\u4e0e\u3057\u307e\u3059\u3002<\/li>\n<\/ul>\n<p>LL-37\u306e\u751f\u7269\u5b66\u306b\u304a\u3051\u308b\u969b\u7acb\u3063\u305f\u7279\u5fb4\u306f\u3001 <strong>\u201c\u5263\u3068\u76fe\u201d\u306e\u30d0\u30e9\u30f3\u30b9<\/strong>: at low concentrations the peptide is dominantly immunomodulatory and tissue-protective, while at high local concentrations the direct membrane-disruptive activity dominates. This concentration-dependent functional switching is one reason why LL-37 has therapeutic-studies interest across both antimicrobial and wound-healing indications, and why detailed dose-response characterisation is critical in any in-vitro or in-vivo protocol. <\/p>\n<h2>Published Evidence<\/h2>\n<p>LL-37 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Antimicrobial-resistance studies<\/strong> \u2014 MRSA\u3001ESBL\u7523\u751f\u8178\u5185\u7d30\u83cc\u79d1\u7d30\u83cc\u3001\u30ab\u30eb\u30d0\u30da\u30cd\u30e0\u8010\u6027\u83cc\u3001\u30d0\u30a4\u30aa\u30d5\u30a3\u30eb\u30e0\u95a2\u9023\u75c5\u539f\u83cc\u306b\u5bfe\u3059\u308b\u5e83\u57df\u6700\u5c0f\u767a\u80b2\u963b\u6b62\u6fc3\u5ea6\uff08MIC\uff09\u30d1\u30cd\u30eb\uff1bAMP\u958b\u767a\u30d1\u30a4\u30d7\u30e9\u30a4\u30f3\u306e\u30d9\u30f3\u30c1\u30de\u30fc\u30ad\u30f3\u30b0<\/li>\n<li><strong>Biofilm studies<\/strong> \u2014 \u30d0\u30a4\u30aa\u30d5\u30a3\u30eb\u30e0\u4e88\u9632\u30a2\u30c3\u30bb\u30a4\u3001\u78ba\u7acb\u3055\u308c\u305f\u30d0\u30a4\u30aa\u30d5\u30a3\u30eb\u30e0\u7834\u58ca\u30a2\u30c3\u30bb\u30a4\u306b\u5bfe\u3059\u308b <em>P. aeruginosa<\/em>, <em>S. aureus<\/em>, Rosu HDL <em>K. pneumoniae<\/em> \u2014 important in cystic-fibrosis and chronic-wound contexts<\/li>\n<li><strong>LPS \/ sepsis studies<\/strong> \u2014 LPS\u4e2d\u548c\u30a2\u30c3\u30bb\u30a4\u3001TLR4\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u89e3\u6790\u3001\u6557\u8840\u75c7\u6027\u30b7\u30e7\u30c3\u30af\u306e\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u30b9\u30c8\u30fc\u30e0\u30e2\u30c7\u30eb<\/li>\n<li><strong>Wound-healing and skin studies<\/strong> \u2014 keratinocyte migration assays, dermal-fibroblast and endothelial wound-closure models; one of the primary peptides in cutaneous wound-healing studies<\/li>\n<li><strong>Psoriasis pathogenesis studies<\/strong> \u2014 LL-37 \/ \u81ea\u5df1DNA \/ \u5f62\u8cea\u7d30\u80de\u69d8\u6a39\u72b6\u7d30\u80de\u8ef8\u306e\u89e3\u6790\uff08LL-37\u306f\u4e7e\u766c\u76ae\u819a\u3067\u904e\u5270\u767a\u73fe\u3057\u3001\u81ea\u5df1DNA\u3068\u8907\u5408\u4f53\u3092\u5f62\u6210\u3057\u3066pDC\u306eTLR9\u3092\u4ecb\u3057\u3066\u514d\u75ab\u5bdb\u5bb9\u3092\u7834\u7dbb\u3055\u305b\u308b\uff09<\/li>\n<li><strong>Atherosclerosis studies<\/strong> \u2014 \u30d7\u30e9\u30fc\u30af\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u5185\u306eLL-37\u3001\u9178\u5316LDL\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u3001\u8840\u7ba1\u708e\u75c7\u30e2\u30c7\u30eb<\/li>\n<li><strong>Oncology<\/strong> \u2014 \u816b\u760d\u30bf\u30a4\u30d7\u306b\u5fdc\u3058\u305f\u9006\u8aac\u7684\u306a\u816b\u760d\u4fc3\u9032\u4f5c\u7528\u3068\u6297\u816b\u760d\u4f5c\u7528\uff08LL-37\u306f\u4e00\u90e8\u306e\u304c\u3093\u3067\u306fFPRL1\u3092\u4ecb\u3057\u3066\u5897\u6b96\u4fc3\u9032\u7684\u306b\u4f5c\u7528\u3057\u3001\u4ed6\u306e\u304c\u3093\u3067\u306f\u816b\u760d\u7d30\u80de\u306e\u76f4\u63a5\u7684\u306a\u819c\u7834\u58ca\u3092\u4ecb\u3057\u3066\u6297\u816b\u760d\u7684\u306b\u4f5c\u7528\u3059\u308b\uff09<\/li>\n<li><strong>Innate-immunity mechanistic studies<\/strong> \u2014 FPRL1\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3001P2X7\u8abf\u7bc0\u3001\u597d\u4e2d\u7403\u7d30\u80de\u5916\u30c8\u30e9\u30c3\u30d7\uff08NET\uff09\u306e\u751f\u7269\u5b66\u3001\u30d3\u30bf\u30df\u30f3D\u3092\u4ecb\u3057\u305fCAMP\u8a98\u5c0e<\/li>\n<\/ul>\n<p>For broader context on innate-immunity and host-defense peptide studies, see <a href=\"https:\/\/medsbase.com\/ja\/kpv-lysine-proline-valine\/\">KPV<\/a> (\u03b1-MSH\u7531\u6765\u306e\u6297\u708e\u75c7\u30c8\u30ea\u30da\u30d7\u30c1\u30c9)\u3001, <a href=\"https:\/\/medsbase.com\/ja\/bpc-157\/\">BPC-157<\/a> (\u591a\u7d4c\u8def\u7d44\u7e54\u4fee\u5fa9\u30da\u30f3\u30bf\u30c7\u30ab\u30da\u30d7\u30c1\u30c9)\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/tb-500\/\">TB-500<\/a> (\u30c1\u30e2\u30b7\u30f3\u30d9\u30fc\u30bf4\u65ad\u7247\u3001\u5e45\u5e83\u3044\u7d44\u7e54\u4fee\u5fa9)\u3002\u5b8c\u5168\u7248\u3092\u898b\u308b <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks LL-37 in 5 mg lyophilized vials. Available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 multi-week MIC panels, biofilm assays, wound-healing experiments, LPS-neutralisation assays, immunomodulation dose-response work<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>LL-37 is supplied as the unmodified linear 37-mer free-acid form (no acylation, no PEGylation, no disulfide bridge). The peptide is sensitive to plastic adsorption \u2014 users should use low-binding tubes for stock storage and dilution. Working concentrations in published assays range from ~0.5 \u00b5g\/mL in chemotaxis assays up to ~50 \u00b5g\/mL in direct-killing antimicrobial assays. <\/p>\n<h2>\u6bd4\u8f03\u65b9\u6cd5 \u2014 LL-37\u5bfeKPV<\/h2>\n<p>LL-37\u3068 <a href=\"https:\/\/medsbase.com\/ja\/kpv-lysine-proline-valine\/\">KPV<\/a> are both used in innate-immunity studies but operate at completely different scales and target different machinery. LL-37 is a full 37-residue host-defense peptide combining direct antimicrobial membrane disruption with FPRL1-mediated immunomodulation. KPV (Lysine-Proline-Valine) is a 3-residue C-terminal fragment of \u03b1-melanocyte-stimulating hormone (\u03b1-MSH) that acts as a focused anti-inflammatory and modest antimicrobial peptide through melanocortin-receptor pathway modulation. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">LL-37<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">KPV<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u7531\u6765<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30d2\u30c8\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3hCAP-18\uff08CAMP\u907a\u4f1d\u5b50\uff09\u306eC\u672b\u7aef<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u03b1-\u30e1\u30e9\u30ce\u30b5\u30a4\u30c8\u523a\u6fc0\u30db\u30eb\u30e2\u30f3\uff08\u03b1-MSH\uff09\u306eC\u672b\u7aef<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a2\u30df\u30ce\u9178\u6570<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">37\u30a2\u30df\u30ce\u9178<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">3\u30a2\u30df\u30ce\u9178<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e3b\u306a\u4f5c\u7528\u6a5f\u5e8f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u4e21\u89aa\u5a92\u6027\u03b1-\u30d8\u30ea\u30c3\u30af\u30b9\u819c\u7834\u58ca + FPRL1\u514d\u75ab\u8abf\u7bc0<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30e1\u30e9\u30ce\u30b3\u30eb\u30c1\u30f3\u7d4c\u8def\u3092\u4ecb\u3057\u305f\u6297\u708e\u75c7\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\uff08NF-\u03baB\u6291\u5236\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u6297\u83cc\u30b9\u30da\u30af\u30c8\u30eb<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5e83\u57df \u2014 \u30b0\u30e9\u30e0\u967d\u6027\u83cc\u3001\u30b0\u30e9\u30e0\u9670\u6027\u83cc\u3001\u30a8\u30f3\u30d9\u30ed\u30fc\u30d7\u30a6\u30a4\u30eb\u30b9\u3001\u771f\u83cc\u3001\u30d0\u30a4\u30aa\u30d5\u30a3\u30eb\u30e0<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u72ed\u57df \u2014 \u4e3b\u306b\u30b0\u30e9\u30e0\u967d\u6027\u83cc\uff1bLL-37\u3088\u308a\u3082\u6570\u6841\u5f31\u3044<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u6297\u708e\u75c7\u4f5c\u7528<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5f37\u529b\uff08LPS\u4e2d\u548c\u4f5c\u7528\u3001\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u8abf\u7bc0\u4f5c\u7528\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Strong (canonical anti-inflammatory studies tripeptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u6b63\u5473\u96fb\u8377<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">+6\uff08\u9ad8\u3044\u30ab\u30c1\u30aa\u30f3\u6027\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">+1<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u819c\u4e2d\u3067\u306e\u69cb\u9020<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u4e21\u89aa\u5a92\u6027\u03b1-\u30d8\u30ea\u30c3\u30af\u30b9<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u660e\u78ba\u306a\u4e8c\u6b21\u69cb\u9020\u306a\u3057\uff08\u77ed\u3044\u7dda\u72b6\u30e2\u30c1\u30fc\u30d5\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u6700\u3082\u7814\u7a76\u3055\u308c\u3066\u3044\u308b\u9069\u5fdc\u75c7<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u6297\u83cc\u85ac\u8010\u6027\u3001\u5275\u50b7\u6cbb\u7652\u3001\u4e7e\u766c<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">IBD\/\u5927\u8178\u708e\u30e2\u30c7\u30eb\u3001\u8178\u306e\u708e\u75c7\u3001\u30a2\u30c8\u30d4\u30fc\u6027\u76ae\u819a\u708e<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on broad-spectrum antimicrobial activity, biofilm disruption, or membrane-pore mechanisms, LL-37 is the canonical reference peptide. For studies focused on melanocortin-pathway anti-inflammatory signalling at the cellular level, <a href=\"https:\/\/medsbase.com\/ja\/kpv-lysine-proline-valine\/\">KPV<\/a> \u306f\u3001\u3088\u308a\u9078\u629e\u7684\u306a\u30c4\u30fc\u30eb\u3067\u3059\u3002\u53c2\u7167\uff1a <a href=\"https:\/\/medsbase.com\/ja\/bpc-157\/\">BPC-157<\/a> for tissue-repair-focused anti-inflammatory studies and <a href=\"https:\/\/medsbase.com\/ja\/tb-500\/\">TB-500<\/a> \u5e83\u7bc4\u306a\u7d44\u7e54\u4fee\u5fa9\u306e\u30d9\u30f3\u30c1\u30de\u30fc\u30af\u7528\u3002 <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 BAC\u6c34\u304c\u5fc5\u8981\u3067\u3059\u304b\uff1f<\/strong> \u51cd\u7d50\u4e7e\u71e5\u54c1\u306e\u5fa9\u5143\u306b\u306f\u6ec5\u83cc\u9759\u83cc\u6c34\u304c\u5fc5\u8981\u3067\u3059\u3002\u672c\u88fd\u54c1\u3068\u4f75\u305b\u3066\u5f53\u793e\u306e <a href=\"\/ja\/bac-water\/\"><strong>BAC Water\uff08\u9759\u83cc\u6c34\uff09<\/strong><\/a> \u2014 30 mL\u30de\u30eb\u30c1\u30c9\u30fc\u30ba\u30d0\u30a4\u30a2\u30eb\u30010.9%\u30d9\u30f3\u30b8\u30eb\u30a2\u30eb\u30b3\u30fc\u30eb\u4fdd\u5b58\u3001USP\u30b0\u30ec\u30fc\u30c9\u3002<\/div>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u3001\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u3001\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8\u2103\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u9577\u671f\u4fdd\u7ba1\u306b\u306f\u3001\u672a\u958b\u5c01\u306e\u30d0\u30a4\u30a2\u30eb\u3092-20\u2103\u3067\u51b7\u51cd\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5\u3055\u308c\u305fLL-37\u306f\u3001\u51b7\u8535\u3067\u6700\u592724\u30f6\u6708\u3001-20\u2103\u3067\u6700\u592736\u30f6\u6708\u5b89\u5b9a\u3067\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306e\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002\u3059\u3079\u3066\u306e\u30ab\u30c1\u30aa\u30f3\u6027\u6297\u83cc\u30da\u30d7\u30c1\u30c9\u3068\u540c\u69d8\u306b\u3001LL-37\u306f <strong>\u30d7\u30e9\u30b9\u30c1\u30c3\u30af\u5438\u7740<\/strong> \u2014 \u6a19\u6e96\u7684\u306a\u30dd\u30ea\u30d7\u30ed\u30d4\u30ec\u30f3\u30c1\u30e5\u30fc\u30d6\u3078\u306e\u308f\u305a\u304b\u306a\u5438\u7740\u3067\u3082\u3001\u7528\u91cf\u53cd\u5fdc\u30c7\u30fc\u30bf\u306b\u5f71\u97ff\u3092\u53ca\u307c\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u4f4e\u5438\u7740\u30c1\u30e5\u30fc\u30d6\uff08\u30b7\u30ea\u30b3\u30f3\u51e6\u7406\u30ac\u30e9\u30b9\u3001Protein LoBind\u3001\u307e\u305f\u306f\u30a6\u30b7\u8840\u6e05\u30a2\u30eb\u30d6\u30df\u30f3\u3067\u30d7\u30ec\u30b3\u30fc\u30c8\u3057\u305f\u30dd\u30ea\u30d7\u30ed\u30d4\u30ec\u30f3\uff09\u3092\u3001\u4fdd\u5b58\u6db2\u306e\u4fdd\u7ba1\u3084\u4f4e\u30bf\u30f3\u30d1\u30af\u8cea\u30a2\u30c3\u30bb\u30a4\u30d0\u30c3\u30d5\u30a1\u30fc\u3067\u306e\u6bb5\u968e\u5e0c\u91c8\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> \u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u9759\u83cc\u6c34\u3092\u6ce8\u5165\u3057\u3066\u304f\u3060\u3055\u3044\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u30025 mg\u30d0\u30a4\u30a2\u30eb\u306e\u5834\u5408\u3001\u9759\u83cc\u6c341.0 mL\u30675 mg\/mL\u306e\u4f5c\u696d\u6fc3\u5ea6\u304c\u5f97\u3089\u308c\u307e\u3059\u30022.0 mL\u3067\u306f2.5 mg\/mL\u306e\u4f5c\u696d\u30b9\u30c8\u30c3\u30af\u304c\u5f97\u3089\u308c\u307e\u3059\u3002\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3066\u304f\u3060\u3055\u3044\u2014\u6fc0\u3057\u304f\u30dc\u30eb\u30c6\u30c3\u30af\u30b9\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u6ce1\u7acb\u3061\u306b\u3088\u308a\u7a7a\u6c17\u304c\u5165\u308a\u3001\u30d8\u30ea\u30c3\u30af\u30b9\u6298\u308a\u305f\u305f\u307f\u304c\u4e71\u308c\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u7c89\u672b\u304c\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u3067\uff08\u901a\u5e381\uff5e2\u5206\uff09\u5f85\u3063\u3066\u304b\u3089\u629c\u304d\u53d6\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u9759\u83cc\u5264\u306b\u611f\u53d7\u6027\u306e\u9ad8\u3044\u7528\u9014\uff08\u7d30\u80de\u57f9\u990a\u5b9f\u9a13\uff09\u3067\u306f\u3001\u6ec5\u83cc\u6c34\u307e\u305f\u306f0.01%\u9162\u9178\u3067\u6eb6\u89e3\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6eb6\u89e3\u5f8c\u306f\u3001\u30d0\u30a4\u30a2\u30eb\u30922\uff5e8 \u00b0C\u3067\u4fdd\u5b58\u3057\u300114\uff5e28\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6fc1\u308a\u3001\u7c92\u5b50\u3001\u307e\u305f\u306f\u8272\u306e\u5909\u5316\u304c\u73fe\u308c\u305f\u5834\u5408\u306f\u5ec3\u68c4\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2>\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>LL-37\u306f\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\u3068\u540c\u3058\u3067\u3059\u304b\uff1f<\/h3>\n<p>LL-37\u306f\u3001\u30d2\u30c8\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\uff08\u4e0d\u6d3b\u6027\u524d\u99c6\u4f53hCAP-18\u3001CAMP\u907a\u4f1d\u5b50\u306b\u30b3\u30fc\u30c9\u3055\u308c\u308b\uff09\u304b\u3089\u653e\u51fa\u3055\u308c\u308b\u6d3b\u6027\u578bC\u672b\u7aef37\u30a2\u30df\u30ce\u9178\u30da\u30d7\u30c1\u30c9\u3067\u3059\u3002\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\u306f\u30d5\u30a1\u30df\u30ea\u30fc\u540d\u3067\u3042\u308a\u3001\u591a\u304f\u306e\u810a\u690e\u52d5\u7269\u7a2e\u306b\u308f\u305f\u3063\u3066\u5b58\u5728\u3057\u307e\u3059\u3002LL-37\u306f\u6d3b\u6027\u578b\u30d2\u30c8\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\u30da\u30d7\u30c1\u30c9\u306e\u56fa\u6709\u306e\u540d\u79f0\u3067\u3059\u3002\u6587\u732e\u3067\u898b\u304b\u3051\u308b\u304b\u3082\u3057\u308c\u306a\u3044\u4ed6\u306e\u540d\u79f0\u2014CAP-18\u304a\u3088\u3073FALL-39\u2014\u306f\u3001\u7570\u306a\u308b\u6b74\u53f2\u7684\u547d\u540d\u898f\u5247\u306b\u3088\u308b\u540c\u3058\u5206\u5b50\u3092\u6307\u3057\u307e\u3059\u3002 <\/p>\n<h3>LL-37\u306f\u30c7\u30a3\u30d5\u30a7\u30f3\u30b7\u30f3\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>LL-37\u3068\u30c7\u30a3\u30d5\u30a7\u30f3\u30b7\u30f3\uff08\u03b1-\u30c7\u30a3\u30d5\u30a7\u30f3\u30b7\u30f3\u304a\u3088\u3073\u03b2-\u30c7\u30a3\u30d5\u30a7\u30f3\u30b7\u30f3\uff09\u306f\u3001\u54fa\u4e73\u985e\u306e\u6297\u83cc\u30da\u30d7\u30c1\u30c9\u306e2\u3064\u306e\u4e3b\u8981\u30d5\u30a1\u30df\u30ea\u30fc\u3067\u3059\u3002\u30c7\u30a3\u30d5\u30a7\u30f3\u30b7\u30f3\u306f\u3088\u308a\u5c0f\u3055\u304f\u3001\u30b7\u30b9\u30c6\u30a4\u30f3\u304c\u8c4a\u5bcc\u3067\u30013\u3064\u306e\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3067\u5b89\u5b9a\u5316\u3055\u308c\u305f\u03b2\u30b7\u30fc\u30c8\u69cb\u9020\u3092\u3068\u308a\u307e\u3059\u3002LL-37\u306f\u3001\u819c\u74b0\u5883\u3067\u4e21\u89aa\u5a92\u6027\u03b1-\u30d8\u30ea\u30c3\u30af\u30b9\u3092\u3068\u308b\u3088\u308a\u9577\u3044\u76f4\u9396\u72b6\u30ab\u30c1\u30aa\u30f3\u30da\u30d7\u30c1\u30c9\u3067\u3042\u308a\u3001\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u67b6\u6a4b\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u4e21\u30af\u30e9\u30b9\u306f\u5e83\u7bc4\u306a\u6297\u83cc\u6d3b\u6027\u3068\u514d\u75ab\u8abf\u7bc0\u4f5c\u7528\u3092\u5171\u6709\u3057\u307e\u3059\u304c\u3001\u69cb\u9020\u7684\u306b\u7570\u306a\u308b\u30e1\u30ab\u30cb\u30ba\u30e0\u3067\u6a5f\u80fd\u3057\u307e\u3059\u3002 <\/p>\n<h3>\u6297\u83cc\u30a2\u30c3\u30bb\u30a4\u306b\u304a\u3051\u308bLL-37\u306e\u5178\u578b\u7684\u306a\u6709\u52b9\u6fc3\u5ea6\u306f\u3069\u308c\u304f\u3089\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u611f\u53d7\u6027\u30b0\u30e9\u30e0\u967d\u6027\u83cc\u304a\u3088\u3073\u30b0\u30e9\u30e0\u9670\u6027\u83cc\u306b\u5bfe\u3059\u308bLL-37\u306e\u516c\u8868\u6700\u5c0f\u767a\u80b2\u963b\u6b62\u6fc3\u5ea6\uff08MIC\uff09\u306f\u3001\u83cc\u682a\u3001\u30a2\u30c3\u30bb\u30a4\u30d0\u30c3\u30d5\u30a1\u30fc\u306e\u30a4\u30aa\u30f3\u5f37\u5ea6\u3001\u30d0\u30a4\u30aa\u30d5\u30a3\u30eb\u30e0\u304b\u6d6e\u904a\u7cfb\u304b\u306a\u3069\u306e\u5f62\u5f0f\u306b\u3088\u3063\u3066\u3001\u4e00\u822c\u7684\u306b1\uff5e32 \u00b5g\/mL\u306e\u7bc4\u56f2\u3067\u3059\u3002\u9ad8\u6fc3\u5ea6\uff0850\uff5e100 \u00b5g\/mL\uff09\u306f\u3001\u76f4\u63a5\u7684\u306a\u819c\u7834\u58ca\u8a66\u9a13\u3084\u30d0\u30a4\u30aa\u30d5\u30a3\u30eb\u30e0\u64b2\u6ec5\u30a2\u30c3\u30bb\u30a4\u306b\u3088\u304f\u4f7f\u7528\u3055\u308c\u307e\u3059\u3002\u514d\u75ab\u8abf\u7bc0\u6027\u306e\u8aad\u307f\u53d6\u308a\uff08\u8d70\u5316\u6027\u3001LPS\u4e2d\u548c\u3001\u30b1\u30e9\u30c1\u30ce\u30b5\u30a4\u30c8\u904a\u8d70\uff09\u3067\u306f\u3001\u901a\u5e38\u306f\u308b\u304b\u306b\u4f4e\u3044\u6fc3\u5ea6\uff080.5\uff5e10 \u00b5g\/mL\uff09\u304c\u4f7f\u7528\u3055\u308c\u307e\u3059\u3002\u3054\u81ea\u8eab\u306e\u30d7\u30ed\u30c8\u30b3\u30fc\u30eb\u306b\u9069\u3057\u305f\u7528\u91cf\u7bc4\u56f2\u306f\u3001\u67fb\u8aad\u4ed8\u304d\u6587\u732e\u304b\u3089\u6c7a\u5b9a\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h3>LL-37\u306b\u304a\u3044\u3066\u30d7\u30e9\u30b9\u30c1\u30c3\u30af\u3078\u306e\u5438\u7740\u304c\u554f\u984c\u3068\u306a\u308b\u7406\u7531\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>LL-37\u306e\u3088\u3046\u306a\u30ab\u30c1\u30aa\u30f3\u6027\u6297\u83cc\u30da\u30d7\u30c1\u30c9\uff08AMP\uff09\u306f\u3001\u7279\u306b\u4f4e\u30bf\u30f3\u30d1\u30af\u8cea\u30d0\u30c3\u30d5\u30a1\u30fc\u4e2d\u3067\u3001\u6a19\u6e96\u7684\u306a\u30dd\u30ea\u30d7\u30ed\u30d4\u30ec\u30f3\u3084\u30dd\u30ea\u30b9\u30c1\u30ec\u30f3\u88fd\u306e\u5b9f\u9a13\u5668\u5177\u8868\u9762\u306b\u8457\u3057\u304f\u5438\u7740\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u4f4e\u6fc3\u5ea6\u306e\u30ab\u30c1\u30aa\u30f3\u6027\u30da\u30d7\u30c1\u30c9\u3067\u306f\u30011\u56de\u306e\u30c1\u30e5\u30fc\u30d6\u79fb\u3057\u66ff\u3048\u306730\uff5e80%\u306e\u640d\u5931\u304c\u6587\u732e\u3067\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u306f\u3001\u7279\u306bMIC\u6e2c\u5b9a\u306e\u5e0c\u91c8\u7cfb\u5217\u306b\u304a\u3044\u3066\u3001\u6d3b\u6027\u306e\u4f53\u7cfb\u7684\u306a\u904e\u5c0f\u8a55\u4fa1\u3092\u5f15\u304d\u8d77\u3053\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u4f4e\u5438\u7740\u30c1\u30e5\u30fc\u30d6\u3092\u4f7f\u7528\u3059\u308b\u3001BSA\u3067\u30c1\u30e5\u30fc\u30d6\u3092\u30d7\u30ec\u30b3\u30fc\u30c8\u3059\u308b\u3001\u307e\u305f\u306f\u30a2\u30c3\u30bb\u30a4\u306e\u8aad\u307f\u53d6\u308a\u306b\u5fdc\u3058\u3066\u5e0c\u91c8\u30d0\u30c3\u30d5\u30a1\u30fc\u306b\u30ad\u30e3\u30ea\u30a2\u30bf\u30f3\u30d1\u30af\u8cea\u3092\u542b\u3081\u308b\u306a\u3069\u306e\u5bfe\u7b56\u3092\u3068\u3063\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h3>LL-37\u306f\u3069\u306e\u3088\u3046\u306b\u3057\u3066\u5fae\u751f\u7269\u819c\u3068\u54fa\u4e73\u985e\u819c\u3092\u533a\u5225\u3059\u308b\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u9078\u629e\u6027\u306f\u819c\u7d44\u6210\u306b\u7531\u6765\u3057\u307e\u3059\u3002\u5fae\u751f\u7269\u819c\uff08\u7279\u306b\u30b0\u30e9\u30e0\u9670\u6027\u83cc\u306e\u5916\u819c\u3084\u30b0\u30e9\u30e0\u967d\u6027\u83cc\u306e\u7d30\u80de\u8cea\u819c\uff09\u306f\u3001\u8ca0\u306b\u5e2f\u96fb\u3057\u305f\u8102\u8cea\uff08\u30db\u30b9\u30d5\u30a1\u30c1\u30b8\u30eb\u30b0\u30ea\u30bb\u30ed\u30fc\u30eb\u3001\u30ab\u30eb\u30b8\u30aa\u30ea\u30d4\u30f3\u3001LPS\u3001\u30ea\u30dd\u30c6\u30a4\u30b3\u9178\uff09\u304c\u8c4a\u5bcc\u3067\u3059\u3002\u54fa\u4e73\u985e\u306e\u7d30\u80de\u8cea\u819c\u306f\u3001\u53cc\u6027\u30a4\u30aa\u30f3\u6027\u306e\u5916\u5c64\uff08\u30db\u30b9\u30d5\u30a1\u30c1\u30b8\u30eb\u30b3\u30ea\u30f3\u3001\u30b9\u30d5\u30a3\u30f3\u30b4\u30df\u30a8\u30ea\u30f3\uff09\u3068\u3001\u4e8c\u91cd\u5c64\u3092\u5b89\u5b9a\u5316\u3055\u305b\u308b\u9ad8\u3044\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u542b\u91cf\u3092\u6301\u3063\u3066\u3044\u307e\u3059\u3002LL-37\u306e\u30ab\u30c1\u30aa\u30f3\u9762\u306f\u3001\u8ca0\u306b\u5e2f\u96fb\u3057\u305f\u5fae\u751f\u7269\u8868\u9762\u306b\u512a\u5148\u7684\u306b\u7d50\u5408\u3057\u307e\u3059\u3002\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u3067\u5b89\u5b9a\u5316\u3055\u308c\u305f\u54fa\u4e73\u985e\u819c\u306f\u3001\u633f\u5165\u306b\u5bfe\u3059\u308b\u611f\u53d7\u6027\u304c\u306f\u308b\u304b\u306b\u4f4e\u304f\u306a\u308a\u307e\u3059\u3002\u9078\u629e\u6027\u306f\u6fc3\u5ea6\u4f9d\u5b58\u7684\u3067\u3042\u308a\u3001\u975e\u5e38\u306b\u9ad8\u3044\u5c40\u6240\u6fc3\u5ea6\u3067\u306fLL-37\u306f\u54fa\u4e73\u985e\u7d30\u80de\u306b\u5bfe\u3057\u3066\u3082\u7d30\u80de\u6bd2\u6027\u3092\u793a\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002 <\/p>\n<h3>LL-37\u6a5f\u80fd\u306e\u300c\u5263\u5bfe\u76fe\u300d\u30e2\u30c7\u30eb\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>The model describes the concentration-dependent functional switching of LL-37: at low concentrations (&lt;5 \u00b5g\/mL) the peptide is dominantly immunomodulatory and tissue-protective \u2014 chemotactic, pro-angiogenic, LPS-neutralising. At high concentrations (&gt;20 \u00b5g\/mL) the direct membrane-disruptive antimicrobial activity dominates. This dual nature underlies LL-37&#8217;s diverse roles in host defense and is one of the reasons careful dose-response characterisation is essential in any in-vitro or in-vivo context. <\/p>\n<h3>LL-37\u3068\u4e7e\u766c\u306e\u95a2\u9023\u6027\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>LL-37 is markedly overexpressed in psoriatic skin lesions and binds avidly to self-DNA and self-RNA released from damaged keratinocytes. These LL-37 \/ self-nucleic-acid complexes activate plasmacytoid dendritic cells via TLR9 (DNA) and TLR7 (RNA), driving the IFN-\u03b1-rich autoimmune-like inflammation that characterises psoriasis. Targeting the LL-37 \/ pDC \/ TLR axis is an active area of psoriasis pharmacology studies. <\/p>\n<h3>\u306a\u305c\u4e00\u90e8\u306e\u304c\u3093\u7814\u7a76\u306f\u816b\u760d\u4fc3\u9032\u6027\u3067\u3001\u4ed6\u306e\u7814\u7a76\u306f\u6297\u816b\u760d\u6027\u306a\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>LL-37\u306b\u306f\u3001\u304c\u3093\u306b\u5bfe\u3059\u308b\u72b6\u6cc1\u4f9d\u5b58\u7684\u306a\u52b9\u679c\u304c\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u4e00\u90e8\u306e\u816b\u760d\u30bf\u30a4\u30d7\uff08\u5375\u5de3\u3001\u4e73\u623f\u3001\u80ba\u3001\u5927\u8178\uff09\u3067\u306f\u3001LL-37\u306e\u9ad8\u767a\u73fe\u304c\u4e88\u5f8c\u306e\u60aa\u5316\u3068\u76f8\u95a2\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u306fFPRL1\u3092\u4ecb\u3057\u305f\u5897\u6b96\u4fc3\u9032\u6027\u304a\u3088\u3073\u8840\u7ba1\u65b0\u751f\u4fc3\u9032\u6027\u306e\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u306b\u3088\u308b\u3082\u306e\u3068\u8003\u3048\u3089\u308c\u307e\u3059\u3002\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30d7\uff08\u80c3\u304c\u3093\u3001\u4e00\u90e8\u306e\u30e2\u30c7\u30eb\u3067\u306e\u9ed2\u8272\u816b\uff09\u3067\u306f\u3001LL-37\u306f\u816b\u760d\u7d30\u80de\u306b\u5bfe\u3057\u3066\u76f4\u63a5\u7684\u306a\u819c\u7834\u58ca\u6027\u306e\u7d30\u80de\u50b7\u5bb3\u52b9\u679c\u3092\u793a\u3057\u3001\u6297\u816b\u760d\u6d3b\u6027\u306f\u3088\u308a\u5f31\u3044\u3067\u3059\u3002\u6b63\u5473\u306e\u52b9\u679c\u306f\u3001\u816b\u760d\u306e\u7a2e\u985e\u3001\u5c40\u6240\u6fc3\u5ea6\u3001FPRL1\u306e\u767a\u73fe\u3001\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306e\u69cb\u6210\u306b\u4f9d\u5b58\u3057\u307e\u3059\u3002 <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u30d2\u30c8\u552f\u4e00\u306e\u30ab\u30c6\u30ea\u30b7\u30b8\u30f3\u6297\u83cc\u30da\u30d7\u30c1\u30c9\uff0837\u30a2\u30df\u30ce\u9178\uff09<br \/>\n\u2705 \u4e21\u89aa\u5a92\u6027\u03b1\u30d8\u30ea\u30c3\u30af\u30b9\uff1b\u6b63\u5473\u96fb\u8377+6<br \/>\n\u2705 \u5e83\u57df\u30b9\u30da\u30af\u30c8\u30eb\uff1a\u30b0\u30e9\u30e0\u967d\u6027\u83cc\u3001\u30b0\u30e9\u30e0\u9670\u6027\u83cc\u3001\u30a8\u30f3\u30d9\u30ed\u30fc\u30d7\u30a6\u30a4\u30eb\u30b9\u3001\u30d0\u30a4\u30aa\u30d5\u30a3\u30eb\u30e0<br \/>\n\u2705 FPRL1\u304a\u3088\u3073LPS\u4e2d\u548c\u3092\u4ecb\u3057\u305f\u514d\u75ab\u8abf\u7bc0\u4f5c\u7528<br \/>\n\u2705 \u6297\u83cc\u85ac\u8010\u6027\u3001\u5275\u50b7\u6cbb\u7652\u3001\u4e7e\u766c\u3001\u816b\u760d\u5b66\u3067\u7814\u7a76<\/p>\n<p><strong>LL-37<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":71408,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6465,6464,6463,5441],"class_list":["post-71392","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cap-18","product_tag-cathelicidin","product_tag-ll-37","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/71392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=71392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/71408"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=71392"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=71392"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=71392"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=71392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}